On Wednesday, Nestle, the Swiss food group expanded its business in the booming skincare market by purchasing the rights to a number of injectable treatments for facial lines and wrinkles for $1.4 billion from Valeant Pharmaceuticals International.

Nestle, which is the world’s largest food group, with brands such as Gerber baby food, Nescafe coffee and KitKat chocolate bars had signaled in February its ambitions in skin health products by taking over the Galderma dermatology venture it had with L’Oreal. Galderma will now become part of a new division called Nestle Skin Health SA , with products ranging from sunscreens and soaps to prescription drugs.

For Valeant, which is based in Quebec, the cash deal clears a potential antitrust hurdle to its proposed $49 billion takeover of Allergan Inc, its U.S. rival, which makes Botox. Nestle is moving more and more towards personal care goods or healthier food products that has greater profit margins and quicker sales growth.

According to Vontobel analysts, the United States market for Botox and other wrinkle fillers was set to grow from $2.5 billion in 2013 to $4.7 billion in 2018, with a compound annual growth of 13.5 percent. Analysts said these figures are quite encouraging and they explain how strategic the deal is for Galderma/Nestle.

Shares of Nestle, who this year performed just ahead of the FTSE Euro first 300 Consumer Goods Index, were up 0.4 percent at 69.85 Swiss francs.

According to Nestle, the deal with Valeant would give them the Canadian and US rights to sell Emervel, Restylane and Perlane injectable cosmetic treatments it already manufactures, in addition to Dysport, a cosmetic treatment owned by Ipsen. Nestle will also acquire Sculptra, a skin filler used for reducing wrinkles and other signs of aging from Valeant.